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Background: Although it is known that first degree relatives of celiac patients have an increased risk for celiac
disease few studies are available on its incidence. We investigated the incidence of serologic conversion and of
new cases of celiac disease among first degree relatives with negative results at a first screening.
Methods: From a total of 634 first degree relatives of 186 biopsy-proven celiac disease patients diagnosed between
October 2000 and October 2010, 450 subjects agreed to participate in the study (Group I), and underwent serologic
screening. Between January 2010 and October 2012, out of the initial group of 450, 205 previously sero-negative
subjects consented to participate in a second stage of the study and undergo new serologic testing (Group II). All
serologically positive individuals of both groups (I and II) were genotyped for celiac disease-predisposing alleles
(HLA-DQ2/DQ8).
Results: 19 subjects (4.2%) out of the 450 subjects of Group I disclosed positive serologic results, presence of DQ2
and/or DQ8 alleles and celiac disease-compatible mucosal abnormalities. The 205 previously negative first degree
relatives from Group II that underwent new serologic testing disclosed eight sero-converted subjects. Mucosal
abnormalities in five of these patients confirmed the diagnosis of celiac disease. During the 10-year period of the
study the incidence of sero-conversion was 8/205 and the incidence of biopsy-proven celiac disease cases
was 5/205.
Conclusions: Our data are coincident with other works on this subject and confirm once again that relatives of
celiac patients, especially first degree relatives are at high risk of developing celiac disease. In view of the relatively
low incidence further studies are needed to try to establish a useful and cost-effective algorithm for follow-up of
relatives of celiac patients.
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Celiac disease (CD), an immune-mediated disorder of
the gastrointestinal tract that eventually can affect se-
veral other organs and systems, may begin in either
childhood or adult life. It is characterized by chronic
inflammation of the small intestinal mucosa resulting in
atrophy of intestinal villi, malabsorption, and a variety of
clinical manifestations. During the last few decades
has become progressively clear that CD is a frequent* Correspondence: pratesiunb@gmail.com
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reproduction in any medium, provided the orcondition, although mainly due to the wide range of its
clinical presentation a proportionally small number of
cases are clinically recognized. It has been considered
that CD affects 0.6 to 1.0% of the population worldwide
[1,2], although these figures can vary widely depending
on the world region under study.
CD was considered uncommon in developing coun-
tries until the 1990s, when the introduction of serologic
screening tests resulted in increased rates of diagnosis in
the Middle East, India, and North Africa [3], and Latin
America [4]. An uneven prevalence for CD has been
detected in different Brazilian regions, ranging from
1:119 to 1:417 in the general population [5,6] and from
1:214 to 1:681 in presumed healthy blood donors [7,8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Figure 1 Flow diagram of the study. *These patients were tested
between 2000 and 2010. **Research conducted between 2010 and
2012.
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factors, dietary habits, and ethnic composition of the
population.
CD has a strong genetic component and its genetic risk
factors have been well characterized, as clearly suggested
by higher prevalence among family members, and higher
concordance rates in monozygotic twins than in dizygotic
twins (83–86% vs 11%) [9]. The human leucocyte antigen
(HLA) system is the major genetic determinant of CD
predisposition, with the presence of specific HLA alleles
accounting for approximately 40% of the disease suscep-
tibility [10].
CD is a condition that can erupt at different life stages
a first negative serologic test does not excludes the
possibility of future onset of the disease. The problem of
the incidence of new cases of CD among previously
seronegative first degree relatives (FDRs) has been the
subject of several papers during the last decade [11-15]
including a recent study from the Southern region of
Brazil [16]. Consequently, in the present study we inves-
tigated the incidence of serologic conversion and of new
cases of CD among FDRs with negative serologic results
at a first screening.
Methods
Study population and study design
From a total of 634 FDRs (parents, siblings and offspring)
of 186 biopsy-proven CD patients (65 males, age range:
1 to 65 years, mean age: 13.0 ± 12.7; 121 females, age
range: 1,1 to 62 years, mean age: 18.2 ± 14.7) who attended
the Research Center for Celiac Disease of the Brasilia
University Hospital and had been diagnosed between
October 2000 and October 2010, 450 subjects [236 par-
ents (99 fathers and 137 mothers, age range: 21 to 75 years,
mean age: 45.9 ± 14.3), 147 siblings (63 brothers and 84
sisters, age range: 6 to 41 years, mean age 20.3 ± 11.7), 67
offspring (38 sons and 29 daughters, age range: 4 to
41 years, mean age: 13.5 ± 8.9)] could be contacted and
agreed to participate in the present study. The Brasilia
University Hospital is a public reference hospital that
predominantly serves the low income population from the
city of Brasilia and surrounding areas (Midwest Region of
Brazil). These individuals usually depend exclusively on
the Brazilian Unified National Health System. They
exhibit mixed ancestry, with a significant contribution of
Europeans intermixed with considerable input of other
races, mainly Afro-descendants and Amerindians. All these
450 FDRs underwent serologic testing utilizing recombi-
nant human transglutaminase antibody assay (IgA-htTG).
All positive results on the tTG test were further confirmed
by the antiendomysial antibody assay (IgA-EMA).
Between January 2010 and October 2012, out of the
initial group of 450 individuals, 205 previously con-
firmed seronegative subjects [118 parents (44 fathersand 74 mothers, age range 21 to 75 years, mean age:
43.4 ± 10.2), 63 siblings (26 brothers and 37 sisters, age
range: 6 to 47 years, mean age: 20.4 ± 11,9), 24 offspring
(17 sons and 7 daughters, age range: 3 to 23 years, mean
age: 13 ± 5.7)] consented to participate in the second
stage of the study and undergo new serologic testing
(IgA- htTG and IgA-EMA) (Group II). The first test of
these 205 FDRs had been carried out at least a year
earlier and all subjects were on a gluten-containing diet
at the time of the second test. Intestinal biopsy was
suggested to all patients that disclosed at least one posi-
tive test. The flow diagram of the study can be seen in
Figure 1.
Serologic markers
All subjects were previously tested for serum immuno-
globulin IgA. The initial serologic screening was per-
formed utilizing the ELISA IgA antitransglutaminase
antibody assay (QUANTA LiteW htTG IgA ELISA,
INOVA Diagnostic Inc., San Diego, CA, U.S.A.). All
positive results, determined according to the manufac-
turer’s recommendation values, were further confirmed
by the IgA-EMA assay tested by indirect immunofluo-
rescence with two independent observers examining all
slides.
Briefly, sera were placed onto 4 μm thick cryosections
of distal monkey oesophagus (INOVA Diagnostic Inc.,
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1:5 with phosphate buffered saline and incubated for
30 min. The final reaction was detected with fluorescein
isothiocyanate (FITC) rabbit anti-human IgA conjugate
(Biosystems, Barcelona, Spain). The result was consi-
dered positive when bright green fluorescence of the
reticulin-like staining of smooth muscle was seen.
HLA typing
To further support the diagnosis of CD all serologically
positive individuals from both groups (group I and
group II) were genotyped for the presence of HLA pre-
disposing alleles for CD. Briefly, genomic DNA was ex-
tracted from peripheral venous blood samples using the
IllustraTMBlood genomicPrep Mini Spin Kit (GE Health-
care, Buckinghamshire, UK). HLA-DQA1*0501 (DQ2 α
chain), HLA-DQB1*02 (DQ2 β chain), HLA-DQA1*0301
(DQ8 α chain) and DQB1*0302 (DQ8 β chain) genotyping
was performed by polymerase chain reaction amplification
using sequencespecific primers (PCR-SSP). For internal
positive amplification control, each PCR reaction included
a primer pair for a conserved region of the DRB1 gene.
The amplified products were separated using 2% agarose
gel, stained with ethidium bromide and then visualized
under a ultraviolet (UV) trans illuminator.Table 1 Clinical and laboratory data of eight CD patients orig
seroconversion (Group II)





1st and 2nd test (m)
1 Sister 6 7 12
2 Sister (twin) 12 16 54
3 Sister 30 37 88
4 Mother 30 37 84
5 Sister 32 35 38
6 Sister 37 39 26
7 Sister and daughter 37 44 89
8 Father 67 75 89
$Patients #Marsh Classification.Ethical issues
The study complies with the principles of the latest Dec-
laration of Helsinki (2008) and was approved by the Ethics
Committee of the Brasilia University School of Health
Sciences. All eligible patients were informed about the ob-
jectives of the research and the potential necessity of small
intestine biopsy. Informed consent was obtained from
adults and from the parents for their children. Additional
consent for publication of their clinical data was obtained
from the patients listed in the Table 1.
Results
No cases of IgA deficiency could be detected among the
study subjects. The search for IgA-htTG antibodies
among the initial 450 FDRs (Group I) yielded 19 positive
results on tTG assay, that were further confirmed by the
IgA-EMA immunofluorescent test. Additionally, HLA
typing revealed the presence of DQ2 and/or DQ8 predis-
posing alleles in all these sero-positive subjects. Intes-
tinal biopsy was suggested to these patients and small
bowel histologic evaluation confirmed the diagnosis of
CD. Consequently, the prevalence of CD among the 450
FDRs of 186 celiac patients was 19/450 (4.2%).
The 205 FDRs of Group II that underwent a new sero-
logic test disclosed eight previously sero-negative FDRsinating from the initial group of 450 FDR that disclosed
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seroconverted subjects underwent a duodenal biopsy that
showed variable degrees of mucosal abnormalities, con-
firming their diagnosis of celiac disease. The charac-
teristics of this second group can be seen in Table 1. The
mean interval of time between the first and the second
test was 51.1 months ± 28.7. During the 10-year period of
the study the incidence of sero-conversion was 8/205 and
the incidence of biopsy- proven CD cases was 5/205.
The incidence rate of sero-conversion in our FDRs
during a period of 10 years was 8/205, corresponding to
an annual incidence of 0.141 (95% - CI: 0.7 - 1.0).
Among the eight FDRs the diagnosis of CD was con-
firmed in five (5/205) which corresponds to an annual
incidence of 0.098 (95% - CI: 0.7 - 1.0).
Discussion
CD is a common disorder, with a prevalence of nearly 1%
in Western populations [17,18]. In countries of high
prevalence a minority of authors maintain the view that
the general population should undergo systematic scree-
ning for this disorder because it fulfills the major criteria
for mass screening [19,20]. Other authors argue against
mass screening pointing to the still incomplete under-
standing of the natural course of the disease, poor ad-
herence to a gluten-free diet, conflicting mortality rate
regarding undiagnosed CD and lack of data regarding
cost-effectiveness [21,22]. Additionally, studies in adults
have identified individuals who were serologically negative
at a first screening, and later underwent sero-conversion,
disclosing villous atrophy on duodenal biopsy [23]. Conse-
quently, at the present time the general consensus is that
there are not enough data to justify screening for CD in
the general population [24]. On the other hand, in at risk
groups, such as patients with type 1 diabetes, autoimmune
thyroid and liver diseases and, as the single most impor-
tant risk factor, a family history of biopsy-proven CD,
screening for CD is recommendable and would probably
have a favorable cost-benefit ratio [21].
HLA typing for DQ2/DQ8 alleles has been suggested as
a second step in previously serologically negative FDRs to
limit the number of subjects for serologic follow-up, since
HLA typing is an efficient tool to discriminate individuals
who will regularly require clinical and serological control
[10,25,26]. The negative predictive value of HLA typing is
high due to the fact that gluten intolerance rarely occurs
in the absence of HLA-predisposing alleles [27]. Although
several PCR kits for HLA sampling are currently available
at a relatively lower cost, their use is not yet covered by
the Brazilian Unified National Health System, and this fact
drastically reduces its practicality in extensive screening
programs in our country.
Studies on prevalence of CD among FDRs of celiac pa-
tients have shown significant variability, probably secondaryto differences on methods of diagnosis (biopsy vs. sero-
logic testing) and country of study. A systematic review
performed by Dubé et al. [28] disclosed an estimated
prevalence of CD in FDRs undergoing intestinal biopsy of
16%. On the other hand, considering that CD is a dynamic
process and the risk of developing the disease is spread
over time, it is expected that FDRs will show not only an
increased prevalence but also an increased incidence of
the disorder. Several studies have focused on this topic
and it has been estimated that between 1.6 and 6.6% of
previously serologically negative FDRs, may seroconvert
within a range of 0.5 to 20 years resulting in an annual in-
cidence ranging from 0.3 to 1.7 [26].
In our study 45.5% of the FDRs (205/450) could be re-
trieved during the follow-up period. Eight patients
showed increased level of IgA-htTG. Three of these
eight patients were IgA-EMA negative and consequently
a definitive diagnosis of CD was not established; one was
asymptomatic and the other two disclosed complaints
compatible with CD. The mother of the patient N°2,
considered of high risk for CD, preferred to start the
child on GFD, omitting the biopsy procedure. The other
two patients also denied consent for biopsy, preferring
to wait for further testing. All these three patients were
re-scheduled for future follow-up.
The data shown in Table 1 reinforce the known fact that
an increased frequency of gluten sensitivity is predomi-
nantly found among females and among siblings. Also of
interest is that two of the new cases (patients 7 and 8)
were members of the same Family of 16 in which, out of
the 11 members that could be retested, five were biopsy-
proven celiac, 10 were carriers of predisposing HLA alleles
and only one was serologically and DQ2/DQ8 negative.
This confirms the known fact that members of families
with multiple cases are at higher risk of developing the
disease [29].
The incidence of 3.9% of sero-conversion found in our
study, in a period of 10 years is similar to the values
found in previous published studies [11-15]. Comparing
with our findings, the increased rate of sero-conversion
found by Nass et al. [16] in the Southern region of Brazil
is probably due to the predominantly European origin
of the population screened, which again highlights the
heterogeneity of the Brazilian racial composition.
Conclusion
Our data are in line with other works on this subject and
confirm once again that relatives of celiac patients, espe-
cially FDRs are at high risk of developing CD. To reach
the best strategy the true incidence in the various age
groups still need further and more powerful studies [30].
To establish an effective algorithm to be applied in our
country is still more difficult in view to the low educa-
tional and economic level of the population that attends
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Unified Health System that still do not consider CD as a
potential public health problem.
Presently, in our department we are performing HLA
typing in all the FDRs and repeating the serologic testing
every two years or previously, depending on the appea-
rance of suggestive CD symptomatology although we
know that this is hardly a strategy that could be genera-
lized to other regions of this country.
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